Benjamin Graham fit · Inversión deep-value defensiva
Is Gyre Therapeutics, Inc. Common Stock (GYRE) a Benjamin Graham Stock?
Meets only 2/7 Graham criteria — likely overpriced or unstable.
34/100
FNo encaja
2/7 criterios cumplidos
Los criterios de Benjamin Graham, aplicados a GYRE
P/E ≤ 15
clave—
P/B ≤ 1.5
clave1.5x
Current ratio ≥ 2
6.2x
Debt / Equity ≤ 1
0.0x
Cómo se valora GYRE en otras estrategias
Datos financieros en vivo
Cap. mercado
$731.67M
PER (TTM)
55.7x
ROIC (TTM)
11.69%
Margen bruto
95.48%
Preguntas frecuentes
What is GYRE's Benjamin Graham fit score?
GYRE scores 34/100 on our Benjamin Graham fit engine — grade F. Meets only 2/7 Graham criteria — likely overpriced or unstable.
Does Benjamin Graham actually own GYRE?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends GYRE.
How often is this score updated?
GYRE's Benjamin Graham fit score is recomputed daily from the latest TTM financials.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Benjamin Graham posea o recomiende GYRE personalmente.